Economic considerations for the use of recombinant human bone morphogenetic protein‐2 in open tibial fractures in Europe: the German model
Authors:
- 24 July 2006
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 22 (sup1) , S19-S22
Abstract
The addition of recombinant human bone morphogenetic protein (rhBMP‐2) to the standard of care, consisting of soft tissue management and intramedullary nailing, in the BMP‐2 Evaluation in Surgery for Tibial Trauma (BESTT) study led to a significantly better outcome for the patient. Reductions in fracture healing time, secondary interventions for delayed fracture healing and infection rates were observed with 1.50 mg/mL rhBMP‐2 compared with the standard of care alone.In Germany the approximate cost of applying one dose of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) to an open tibial fracture is €2970. The current German-Diagnosis-Related Group reimbursement system provides one flat rate per hospital stay or treatment case, and does not take into account the costs of rhBMP‐2 application. Therefore there is no reimbursement for the price of rhBMP‐2 for hospitals by health insurance companies. However, the above mentioned improvements in medical outcome could lead to important savings fo...Keywords
This publication has 3 references indexed in Scilit:
- Factors affecting rates of infection and nonunion in intramedullary nailingThe Journal of Bone and Joint Surgery. British volume, 2004
- A Cost Analysis of Bone Morphogenetic Protein Versus Autogenous Iliac Crest Bone Graft in Single-Level Anterior Lumbar FusionOrthopedics, 2003
- Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bonesJournal of Bone and Joint Surgery, 1976